Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $59.00 Price Target at Wedbush

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective upped by Wedbush from $58.00 to $59.00 in a research report released on Wednesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

A number of other research firms have also recently weighed in on KNSA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Sunday. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Finally, Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA opened at $52.99 on Wednesday. The stock has a 50-day simple moving average of $46.26 and a two-hundred day simple moving average of $43.04. The firm has a market capitalization of $4.06 billion, a P/E ratio of 71.61 and a beta of 0.06. Kiniksa Pharmaceuticals International has a fifty-two week low of $24.85 and a fifty-two week high of $54.31.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to analyst estimates of $207.12 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 EPS. As a group, analysts forecast that Kiniksa Pharmaceuticals International will post 1.09 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at approximately $628,554.60. The trade was a 51.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the sale, the chief accounting officer owned 27,418 shares of the company’s stock, valued at approximately $1,280,146.42. This trade represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 74,578 shares of company stock worth $3,489,072 in the last quarter. Corporate insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $31,000. Smartleaf Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $36,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 results beat expectations — Kiniksa reported $0.27 EPS vs. consensus $0.18 and revenue of $214.3M (up ~55.5% YoY), driven by ARCALYST product growth. Strong beat and high-margin progress support near-term earnings confidence. Press Release
• Positive Sentiment: FY‑2026 revenue guidance was raised to $930M–$945M vs. Street ~$912.7M — this upward guidance is a direct positive signal for revenue trajectory and model revisions. Guidance Release
• Positive Sentiment: Product momentum: ARCALYST net product revenue reported at $214.3M in Q1 and management increased 2026 ARCALYST expectations — supports revenue durability and valuation multiple expansion. Product Revenue Release
• Positive Sentiment: Pipeline catalysts: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 and a Phase 3 pivotal trial anticipated to start by year‑end — upcoming readouts could be meaningful share-price catalysts. Pipeline Release
• Positive Sentiment: Analyst upgrades and price‑target raises — multiple firms lifted targets (Jefferies to $71, Citigroup to $60, Canaccord to $64, Wedbush to $59, Wells Fargo to $57), reflecting higher revenue/earnings expectations and driving buy-side interest. Analyst Coverage More Analyst Notes
• Neutral Sentiment: Company materials and call: Q1 earnings slide deck and transcript are available for investors who want detail on channel dynamics, margins and guidance assumptions. Use these to validate the upbeat narrative. Earnings Presentation Call Transcript
• Negative Sentiment: Insider sale: Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a pre‑arranged Rule 10b5‑1 plan, reducing his stake ~51%. While pre‑planned, insider selling can still weigh on sentiment and may contribute to near‑term price pressure. SEC Filing Insider Trade Detail

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.